Durable Response to Carboplatin, Etoposide, Nivolumab, and Ipilimumab in Metastatic High-Grade Neuroendocrine Carcinoma of the Gallbladder

Pancreas. 2020 Feb;49(2):e19-e20. doi: 10.1097/MPA.0000000000001480.
No abstract available

Publication types

  • Case Reports
  • Letter

MeSH terms

  • Antineoplastic Combined Chemotherapy Protocols / therapeutic use*
  • Carboplatin / administration & dosage
  • Carcinoma, Neuroendocrine / drug therapy*
  • Carcinoma, Neuroendocrine / genetics
  • Carcinoma, Neuroendocrine / metabolism
  • Etoposide / administration & dosage
  • Female
  • Gallbladder / drug effects*
  • Gallbladder / metabolism
  • Gallbladder / pathology
  • Humans
  • Ipilimumab / administration & dosage
  • Ki-67 Antigen / analysis
  • Middle Aged
  • Mutation
  • Neoplasm Grading
  • Neoplasm Metastasis
  • Nivolumab / administration & dosage
  • Retinoblastoma Binding Proteins / genetics
  • Treatment Outcome
  • Tumor Suppressor Protein p53 / genetics
  • Ubiquitin-Protein Ligases / genetics

Substances

  • Ipilimumab
  • Ki-67 Antigen
  • RB1 protein, human
  • Retinoblastoma Binding Proteins
  • Tumor Suppressor Protein p53
  • Nivolumab
  • Etoposide
  • Carboplatin
  • Ubiquitin-Protein Ligases